ProfileGDS5678 / 1449108_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 81% 77% 78% 83% 82% 52% 58% 80% 84% 81% 77% 79% 79% 80% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.6977881
GSM967853U87-EV human glioblastoma xenograft - Control 25.2955177
GSM967854U87-EV human glioblastoma xenograft - Control 35.3331578
GSM967855U87-EV human glioblastoma xenograft - Control 46.2899583
GSM967856U87-EV human glioblastoma xenograft - Control 55.9222882
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.3515152
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.5657958
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.6929680
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.2151784
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.8704281
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.2557377
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.5252479
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.4514779
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.6400880